1. Home
  2. SQFT vs GNPX Comparison

SQFT vs GNPX Comparison

Compare SQFT & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Presidio Property Trust Inc.

SQFT

Presidio Property Trust Inc.

HOLD

Current Price

$2.40

Market Cap

5.5M

Sector

Real Estate

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$2.27

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SQFT
GNPX
Founded
1999
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5M
6.4M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
SQFT
GNPX
Price
$2.40
$2.27
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
27.7K
1.6M
Earning Date
03-27-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$17,525,365.00
N/A
Revenue This Year
$23.63
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.31
$1.71
52 Week High
$23.00
$55.00

Technical Indicators

Market Signals
Indicator
SQFT
GNPX
Relative Strength Index (RSI) 30.91 44.33
Support Level $2.31 $2.10
Resistance Level $2.58 $3.11
Average True Range (ATR) 0.26 0.40
MACD -0.07 -0.02
Stochastic Oscillator 3.37 10.45

Price Performance

Historical Comparison
SQFT
GNPX

About SQFT Presidio Property Trust Inc.

Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: